Research demonstrates mTOR inhibition affects galectin-1 in KMT2A-rearranged acute lymphoblastic leukemia, suggesting a new treatment approach.
Targeting mTOR signaling contributes to the regulation of Galectin-1 immune checkpoint activity in KMT2Ar-ALL. Inhibition of mTOR may represent a potential therapeutic strategy to overcome immune evasion in this leukemia subtype.
No takes yet. Share an insight, caveat, or question.
Pawlik et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: